2018162Vu Reference List

Intramuscular Tranexamic Acid in Tactical and Combat Settings

Spring 2018

Erik N. Vu, MSM, MD; Wilson C. Y. Wan, MD; Titus Yeung, MD; Dave Callaway, MD

References

  1. Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6 suppl 5):S431-S437.
  2. Butler FK Jr, Blackbourne LH, Battlefield trauma care then and now: a decade of Tactical Combat Casualty Care. J Trauma Acute Care Surg. 2013;73(6 suppl 5):S395-402.
  3. Shakur H, Roberts I, Bautista R, et al. Effects of tran-examic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
  4. Morrison JJ, Dubose JJ, Rasmussen TE, et al. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147(2):113-119.
  5. Engels PT, et al. IV access in bleeding trauma patients: a performance review. Injury, 2014;45(1):77-82.
  6. Nadler R, et al. Intravenous access in the prehospital [combat] settings: what can be learned from point-of-injury experience. J Trauma Acute Care Surg, 2015;79(2):221-226.
  7. Rizoli SB, et al. Clotting factor deficiency in early trauma-associated coagulopathy. J Trauma, 2011;71(5 suppl 1):S427-S434.
  8. Brohi K, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis, J Trauma-Injury Infection Crit Care. 2008;64(5):1211-1217.
  9. Holcomb JB, et al. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) Study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013;148(2):127-136.
  10. Holcomb JB, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma. The PROPPR Randomized Clinical Trial. JAMA. 2015;313(5):471-482.
  11. AP Cap, et al. Timing and location of blood product transfusion and outcomes in massively transfused combat casualties. J Trauma Acute Care Surg. 2012;73(2 suppl 1):S89-S94.
  12. Cotton BA, Reddy N, Hatch QM, et al. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Ann Surg. 2011;254(4):598-605.
  13. Mrochuk M, O’Dochartaigh D, Chang E. Rural trauma patients cannot wait: tranexamic acid administration by helicopter emergency medical services. Air Med J. 2015;34(1):37-39.
  14. Cole E, Davenport R, Willett K, et al. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg. 2015;261(2):390-394.
  15. Tengborn L, Blomback M, Berntorp E. Tranexamic acid: an old drug still going strong and making a revival. Thromb Res. 2014; Nov 20.
  16. Zehtabchi S, Abdel Baki SG, Falzon L, et al. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med. 2014;32(12):1503-1509.
  17. Nadler R, Gendler S, Benov A, et al. Tranexamic acid at the point of injury: the Israeli combined civilian and military experience. J Trauma Acute Care Surg. 2014;77(3 suppl 2):S146-S150.
  18. Ackery A, Rizoli S. Tranexamic acid for trauma-related hemorrhage. CMAJ. 2014;186(15):E587.
  19. Dakir A, Ramalingam B, Ebenezer V, et al. Efficacy of tranexamic acid in reducing blood loss during maxillofacial trauma surgery: a pilot study, J Clin Diagn Res. 2014;8(5):ZC06-ZC08.
  20. Valle EJ, Allen CJ, Van Haren RM, et al. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014;76(6):1373-1378.
  21. ailey AM, Baker SN, Weant KA. Tranexamic acid for trauma-related hemorrhage. Adv Emerg Nurs J. 2014;36(2):123c131.
  22. Schochl H, Schlimp CJ, Maegele M. Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? Shock. 2014;41(suppl 1):44-46.
  23. Lipsky AM, Abramovich A, Nadler R, et al. Tranexamic acid in the prehospital setting: Israel Defense Forces’ initial experience. Injury. 2014;45:66-70.
  24. Mitra B, Mazur S, Cameron PA, et al. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australas. 2014;26(2):194-197.
  25. Livingstone C. Tranexamic acid in patients with major injuries and blood loss. Emerg Nurse. 2013;21(8):24-26.
  26. Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, et al. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial, BMC Emerg Med. 2013;13:20.
  27. Vu EN, Schlamp RS, Wand RT, et al. Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation. Air Med J. 2013;32(5):289-292.
  28. Perel P, Prieto-Merino D, Shakur H, et al. Development and validation of a prognostic model to predict death in patients with traumatic bleeding, and evaluation of the effect of tranexamic acid on mortality according to baseline risk: a secondary analysis of a randomised controlled trial. Health Technol Assess. 2013;17(24):1-45, v-vi.
  29. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1-79.
  30. Rappold JF, Pusateri AE. Tranexamic acid in remote damage control resuscitation. Transfusion. 2013;53(suppl 1):96S-99S.
  31. Pusateri AE, Weiskopf RB, Bebarta V, et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39(2):121-126.
  32. Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality. Prescrire Int. 2013;22(140):189-190.
  33. Morrison JJ, Ross JD, Dubose JJ, et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg. 2013;148(3):218-225.
  34. Perel P, Ker K, Morales Uribe CH, et al. Tranexamic acid for reducing mortality in emergency and urgent surgery. Cochrane Database Syst Rev. 2013;1.
  35. Roberts I, Perel P, Prieto-Merino D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012;345:e5839.
  36. Levi M. Should antifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol. 2012;25(3):385-388.
  37. Weber BJ, Kjelland CB. The use of tranexamic acid for trauma patients? CJEM. 2012;14(1):53-56.
  38. Perel P, Al-Shahi Salman R, Kawahara T, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury-a nested randomised, placebo-controlled trial. Health Technol Assess. 2012;16(13):iii-xii, 1c54.
  39. Ker K, Kiriya J, Perel P, et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med. 2012;12:3.
  40. Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012;12:CD004896.
  41. Cap AP, Baer DG, Orman JA, et al. Tranexamic acid for trauma patients: a critical review of the literature. J Trauma. 2011;71(1 suppl):S914.
  42. CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ. 2011;343:d3795.
  43. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101, 101 e1-2.
  44. Hunt BJ. The current place of tranexamic acid in the man-agement of bleeding, Anaesthesia. 2015;70(suppl 1):50-53, e18.
  45. Zhang F, et al. Effectiveness of tranexamic acid in reducing blood loss in spinal surgery: a meta-analysis. BMC Musculoskelet Disord. 2014;15(1):448.
  46. Breau RH, et al. The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis. Transfus Med Rev. 2014;28(3):145-155.
  47. Whiting DR, et al. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res. 2014;472(1):66-72.
  48. Zehtabchi S, et al. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med. 2014;32(12):1503-1509.
  49. Zhang Y, et al. Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty. Orthopedics. 2014;37(9):e775-e782.
  50. Moen CA, et al. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg. 2013;17(6):991-994.
  51. Fu DJ, et al. Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Traumatol. 2013;16(2):67v76.
  52. Gruen RL, et al. Trauma and tranexamic acid. Med J Aust. 2013;199(5):310-311.
  53. No authors listed. Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality. Prescrire Int. 2013; 22(140):189v190.
  54. No authors listed. Tranexamic acid and thrombosis. Prescrire Int. 2013;22(140):182-183.
  55. Gybel MK, et al. Cardiac arrest caused by massive pulmonary embolism during treatment with tranexamic acid. Ugeskr Laeger. 2013;175(20):1426-1427.
  56. Munoz Gomez M, Paramo Fernandez JA. Intravenous administration of tranexamic acid to decrease bleeding and transfusion in knee and hip prosthetic surgery: is it safe and cost-effective? Med Clin (Barc). 2013;141(5):207-209.
  57. Panteli MC, et al. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis, Knee. 2013; 20(5):300-309.
  58. Leminen H, Hurskainen R. Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. Int J Womens Health. 2012;4:413-421.
  59. Yang ZG, et al. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012;94(13):1153-1159.
  60. Onodera TT, et al. Risk of deep venous thrombosis in drain clamping with tranexamic acid and carbazochrome sodium sulfonate hydrate in total knee arthroplasty. J Arthroplasty. 2012;27(1):105-108.
  61. Ross J, Al-Shahi Salman R. The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. Curr Drug Saf. 2012;7(1):44-54.
  62. Krivokuca I, Lammers JW. Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. Clin Appl Thromb Hemost. 2011;17(1):106-107.
  63. Alshryda SP, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis, J Bone Joint Surg Br. 2011;93(12):1577-1585.
  64. Marquez-Martin ED, et al. Endobronchial administration of tranexamic acid for controlling pulmonary bleeding: a pilot study. J Bronchology Interv Pulmonol. 2010;17(2):122-125.
  65. Ide MD, et al. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesthesiol. 2010;24(1):96-106.
  66. Sundstrom AH, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the -General Practice Research Database. BJOG. 2009;116(1):91-97.
  67. Kagoma YK, et al. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thrombosis Res. 2009;123(5):687-696.
  68. Escher R. Extensive venous thrombosis following administration of high-dose glucocorticosteroids and tranexamic acid in relapsed Evans syndrome. Blood Coagul Fibrinolysis. 2008;19(7):741-742.
  69. Ghosh K. Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis, Thromb Haemost. 2008;100(1):162-164.
  70. Gluud LL, et al. Systematic review: tranexamic acid for upper gastrointestinal bleeding, Aliment Pharmacol Therap. 2008; 27(9):752-758.
  71. Fraser IS, et al. A benefit-risk review of systemic haemostatic agents-part 1: in major surgery. Drug Safety. 2008;31(3):217-230.
  72. Ip PP, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug–induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol. 2007 Aug;31(8):1215-24.
  73. De Wolf A, Abecassis M. Is antifibrinolytic drug use in liver transplantation associated with an increased risk of thromboembolic events? Commentary. Nat Clin Pract Gastroenterol Hepatol. 2007;4(8):422-423.
  74. Molenaar IQ, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transpl. 2007;7(1):185-194.
  75. Groenland TH, Porte RJ. Antifibrinolytics in liver transplantation. Int Anesthesiol Clin. 2006;44(3):83-97.
  76. Hynes MC, et al. The use of tranexamic acid to reduce blood loss during total hip arthroplasty: an observational study. Ann R Coll Surg Engl. 2005;87(2):99-101.
  77. Idbaih AI, et al. Thrombotic cocktail in stroke. Neurology. 2005;64(2):334.
  78. Levin MD, et al. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica. 2003;88(6):Ecr21.
  79. Taparia M, et al. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol. 2002;68(5):307-309.
  80. Berntorp EC, et al. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714-715.
  81. Howes JP, et al. Tranexamic acid reduces blood loss after knee arthroplasty. J Bone Joint Surg Br. 1996;78(6):995-996.
  82. Lindoff C, et al. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993;70(2):238-240.
  83. Bekassy Z, Astedt B. Treatment with the fibrinolytic inhibitor tranexamic acid-risk for thrombosis? Acta Obstet Gynecol Scand. 1990;69(4):353-354.
  84. Snir MR, et al. Central venous stasis retinopathy following the use of tranexamic acid, Retina. 1990;10(3):181-184.
  85. Woo KS, et al. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989;43(12):465-466.
  86. Woo KS, et al. Massive pulmonary thromboembolism after antifibrinolytic therapy. Ann Emerg Med. 1989;18(1):116-117.
  87. Endo Y, et al. Idiopathic thrombocytopenic purpura, associated with deep vein thrombosis induced by tranexamic acid. Rinsho Ketsueki. 1988;29(2):186-188.
  88. Humbert P, et al. Tranexamic acid and thrombosis of the superior longitudinal sinus. Therapie. 1987;42(1):65-66.
  89. Agnelli G, et al. Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report. Br J Obstet Gynaecol. 1982;89(8):681-682.
  90. No authors listed. Thromboembolism and eye diseases caused by tranexamic acid. Lakartidningen. 1980;77(52):4974-4975.
  91. Gelmers HJ. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochir (Wien). 1980;52(1-2):45-50.
  92. Davies D, Howell DA. Tranexamic acid and arterial thrombosis. Lancet. 1977;1(8001):49.
  93. Rydin E, Lundberg PO. Tranexamic acid and intracranial thrombosis [letter]. Lancet. 1976;2(7975):49.
  94. Nadler R, et al. Tranexamic acid at the point of injury: the Israeli combined civilian and military experience. J Trauma Acute Care Surgery. 2014;77(3 suppl 2):S146-S150.
  95. Ackery A, Rizoli S. Tranexamic acid for trauma-related hemorrhage. CMAJ. 2014;186(15):E587.
  96. Valle EJ, Allen CJ, Van Haren RM, et al. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014;76(6):1373-1378.
  97. Bailey AM, Baker SN, Weant KA. Tranexamic acid for trauma-related hemorrhage. Adv Emerg Nursing J. 2014;36(2):123-131; quiz 32-33.
  98. Mitra B, Mazur S, Cameron PA, et al. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australasia. 2014;26(2):194-197.
  99. Theusinger OM, Stein P, Spahn DR. Applying ‘Patient Blood Management’ in the trauma center. Curr Opin Anaesthesiol. 2014;27(2):225-232.
  100. Schochl H, Schlimp CJ, Maegele M. Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? Shock. 2014;41(suppl 1):44-46.
  101. Harvey V, Perrone J, Kim P. Does the use of tranexamic acid improve trauma mortality? Ann Emerg Med. 2014;63(4):460-462.
  102. Eckert MJ, Wertin TM, Tyner SD, et al. Tranexamic acid administration to pediatric trauma patients in a combat setting: the Pediatric Trauma and Tranexamic Acid Study (PED-TRAX). J Trauma Acute Care Surg. 2014;77(6):852-858.
  103. Stensballe J, Ostrowski SR, Johansson PI. Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol. 2014;27(2):212-218.
  104. Lipsky AM, Abramovich A, Nadler R, et al. Tranexamic acid in the prehospital setting: Israel Defense Forces’ initial experience. Injury. 2014;45(1):66-70.
  105. Livingstone C. Tranexamic acid in patients with major injuries and blood loss. Emerg Nurse. 2013;21(8):24-26.
  106. Vu EN, Schlamp RS, Wand RT, et al. Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation. Air Medical J. 2013;32(5):289-292.
  107. Napolitano LM, Cohen MJ, Cotton BA, et al. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013;74(6):1575-1586.
  108. Georgiou C, Neofytou K, Demetriades D. Local and systemic hemostatics as an adjunct to control bleeding in trauma. Am Surgeon. 2013;79(2):180-187.
  109. Rappold JF, Pusateri AE. Tranexamic acid in remote damage control resuscitation. Transfusion. 2013;53(suppl 1): 96S-99S.
  110. Pusateri AE, Weiskopf RB, Bebarta V, et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39(2):121-126. PMID:23222525.
  111. Goodloe JM, Howerton DS, McAnallen D, et al. TXA: a difference-maker for trauma patients. J Emerg Med Serv. 2013;38(4):60-65.
  112. Goodloe JM, Howerton DS, McAnallen D, et al. How can tranexamic acid help in EMS? TXA offers new hope for an old challenge in traumatic hemorrhagic shock. EMS World. 2013;42(5):I5-I6.
  113. Germans MR, Post R, Coert BA, et al. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials [Electronic Resource]. 2013;14:143. TRIAL REGISTRATION: Nederlands Trial Register (Dutch Trial Registry) number NTR3272.
  114. Gruen RL, Jacobs IG, Reade MC. Trauma and tranexamic acid. Med J Australia. 2013;199(5):310-311.
  115. Reade MC, Pitt V, Gruen RL. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;40(2):160-161.
  116. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17(2).
  117. Riha GA, Schreiber MA. Update and new developments in the management of the exsanguinating patient. J Intens Care Med. 2013;28(1):46-57.
  118. Schochl H, Schlimp CJ, Voelckel W. Potential value of pharmacological protocols in trauma. Curr Opin Anaesthesiol. 2013;26(2):221-229.
  119. Morrison JJ, Ross JD, Dubose JJ, et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg. 2013;148(3):218-225.
  120. Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012;12:CD004896.
  121. Gruen RL, Reade MC. Administer tranexamic acid early to injured patients at risk of substantial bleeding, BMJ. 2012; 345:e7133.
  122. Roberts I, Perel P, Prieto-Merino D, et al; Collaborators CRASH. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012;345:e5839.
  123. Boling B, Moore K. Tranexamic acid (TXA) use in trauma. J Emerg Nursing. 2012;38(5):496-497.
  124. Levi M. Should antifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol. 2012;25(3):385-388.
  125. Ker K, Kiriya J, Perel P, et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med. 2012;12:3.
  126. Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al; Collaborators CRASH. CRASH-3: tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial, Trials [Electronic Resource]. 2012;13:87. TRIAL REGISTRATION: Current Controlled Trials ISRCTN15088122; ClinicalTrials.gov NCT01402882.
  127. Grottke O. Coagulation management. Curr Opin Crit Care. 2012;18(6):641-646.
  128. Theusinger OM, Madjdpour C, Spahn DR. Resuscitation and transfusion management in trauma patients: emerging concepts. Curr Opin Crit Care. 2012;18(6):661-670.
  129. Perel P, Al-Shahi Salman R, Kawahara T, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury-a nested randomised, placebo-controlled trial, Health Technology Assessment (Winchester, England). 2012;16(13):iii-xii, 1-54. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86750102.
  130. Culligan WB, Tien HC. Tranexamic acid autoinjector for prehospital care of noncompressible hemorrhage. J Trauma-Injury Infection Crit Care. 2011;71(5 suppl 1):S501-S502.
  131. Yeguiayan JM, Rosencher N, Vivien B. Early administration of tranexamic acid in trauma patients. Lancet. 2011; 378(9785):27-28; author reply 8.
  132. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101, 101.e1-e2.
  133. Curry N, Hopewell S, Doree C, et al. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care. 2011;15(2).
  134. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
  135. Griffee MJ, DeLoughery TG, Thorborg PA. Coagulation management in massive bleeding. Curr Opin Anaesthesiol. 2010;23(2):263-268.
  136. Mylankal KJ, Wyatt MG. Control of major haemorrhage. Surgery. 2010;28(11):556-562.
  137. Levine JM. Critical care management of subarachnoid hemorrhage. Curr Treat Options Neurol. 2009;11(2):126-136.
  138. Wise A, Clark V. Strategies to manage major obstetric haemorrhage. Curr Opin Anaesthesiol. 2008;21(3):281-287.
  139. Cocchi MN, Kimlin E, Walsh M, et al. Identification and resuscitation of the trauma patient in shock. Emerg Med Clin N Am. 2007;25(3):623-642.
  140. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11(R17).
  141. Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur Heart J Suppl. 2006;8(G):G38-G45.
  142. Bugge W, Hjelmeland K, Soreide E, et al. Transfusion vs. alternative treatment modalities in acute bleeding: a systematic review. Acta Anaesthesiol Scand. 2006;50(8):920-931.
  143. Bailey AM, Baker SN, Weant KA. Tranexamic acid for trauma-related hemorrhage. Adv Emerg Nurs J. 2014;36(2):123-131; quiz 32-33.
  144. Waldow T, Szlapka M, Haferkorn M, et al. Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc. 2013;55(4):457-468.
  145. Iwai T, Tsuji S, Tomita T, et al. Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. Int Orthop. 2013 Mar;37(3):441-415.
  146. Grassin-Delyle S, Couturier R, Abe E, et al. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology. 2013;118(4):853-862.
  147. Koster A, Borgermann J, Zittermann A, et al. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome, Br J Anaesth. 2013;110(1):34-40.
  148. Abbasi H, Behdad S, Ayatollahi V, et al. Comparison of two doses of tranexamic acid on bleeding and surgery site quality during sinus endoscopy surgery. Adv Clin Exp Med. 2012;21(6):773-780.
  149. Maniar RN, Kumar G, Singhi T, et al. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012;470(9):2605-2612.
  150. Bojko B, Vuckovic D, Mirnaghi F, et al. Therapeutic monitoring of tranexamic acid concentration: high-throughput analysis with solid-phase microextraction. Ther Drug Monit. 2012;34(1):31-37.
  151. Jimenez JJ, Iribarren JL, Brouard M, et al. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose–dependent, phase IV clinical trial. J Cardiothorac Surg. 2011;6:138.
  152. Keyl C, Uhl R, Beyersdorf F, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg. 2011;39(5):e114-e121.
  153. Sander M, Spies CD, Martiny V, et al. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care. 2010;14(4):R148.
  154. Murkin JM, Falter F, Granton J, et al. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010;110(2):350-353.
  155. Colomina MJ, Bago J, Fuentes I, Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine 2008;33:2577-2580, Spine (Phila Pa 1976). 2009;34(16):1740-1741.
  156. Nuttall GA, Gutierrez MC, Dewey JD, et al. A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22(2):230-235.
  157. Casati V. About dosage schemes and safety of tranexamic acid in cardiac surgery. Anesthesiology. 2003;99(1):236.
  158. Puigdellivol E, Carral ME, Moreno J, et al. Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol. 1985;23(6):298-301.
  159. Abbara C, Rousseau JM, Lelievre B, et al. Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Br J Pharmacol. 2010;161(8):1857-1867.
  160. Corvino TF, Nahata MC, Angelos MG, et al. Availability, stability, and sterility of pralidoxime for mass casualty use. Ann Emerg Med. 2006;47(3):272-277.
  161. Jovanovic D. Pharmacokinetics of pralidoxime chloride: a comparative study in healthy volunteers and in organophosphorus poisoning. Arch Toxicol. 1989;63(5):416-418.
  162. Edwards ES, Gunn R, Simons ER, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol. 2013;111(2):132-137.
  163. Sclar DA. Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery. Ther Clin Risk Manage. 2013;9(1):149-151.
  164. Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol. 2006;117(2):398-403.
  165. Graf CJ, Woodworth JR, Seger ME, et al. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci. 1999;88(10):991-995.
  166. Pontiroli AE, Calderara A, Perfetti MG, et al. Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. Eur J Clin Pharmacol. 1993;45(6):555-558.
  167. Muhlhauser I, Koch J, Berger M. Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care. 1985;8(1):39-42.
  168. Garnett WR, Barr WH, Edinboro LE, et al. Diazepam autoinjector intramuscular delivery system versus diazepam rectal gel: a pharmacokinetic comparison. Epilepsy Res. 2011;93(1):11-16.
  169. Lamson MJ, Sitki-Green D, Wannarka GL, et al. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single–centre study. Clin Drug Investig. 2011;31(8):585-597.
  170. Abbara C, Rousseau JM, Turcant A, et al. Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. Br J Pharmacol. 2009;157(8):1390-1397.
  171. Lehmann C, Wannarka GL. Bioavailability and dose proportionality of intramuscular diazepam administered by autoinjector. J Clin Pharmacol. 2008;48(4):436-444.
  172. Elisabeth R, Treluyer JM, Pons G. Pharmacokinetic optimisation of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet. 1999;36(6):409-424.
  173. Hung OR, Dyck JB, Varvel J, et al. Comparative absorption kinetics of intramuscular midazolam and diazepam. Can J Anaesth. 1996;43(5 Pt 1):450-455.
  174. Nilsson A. Pharmacokinetics of benzodiazepines and their antagonists. Bailliere’s Clin Anaesthesiol. 1991;5(3):615-634.
  175. Brazeau GA, Fung HL. Effect of organic cosolvent-induced skeletal muscle damage on the bioavailability of intramuscular [14C]diazepam, J Pharm Sci. 1990;79(9):773-777.
  176. Saletu B, Anderer P, Kinsperger K, et al. Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping. Int Clin Psychopharmacol. 1988;3(4):287-323.
  177. Bertler A, Lindgren S, Magnusson JO, et al. Intramuscular bioavailability of chlorazepate as compared to diazepam. Eur J Clin Pharmacol. 1985;28(2):229-230.
  178. Divoll M, Greenblatt DJ, Ochs HR, et al. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg. 1983;62(1):1-8.
  179. von Dardel O, Mebius C, Mossberg T, et al. Fat emulsion as a vehicle for diazepam. A study of 9492 patients. Br J Anaesth. 1983;55(1):41-47.
  180. Magnussen I, Oxlund HR, Alsbirk KE, et al. Absorption of diazepam in man following rectal and parenteral administration. Acta Pharmacol Toxicol (Copenh). 1979;45(2):87-90.
  181. Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm. 1977;34(9):965-968.
  182. Korttila K, Sothman A, Andersson P. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. Acta Pharmacol Toxicol (Copenh). 1976;39(1):104-117.
  183. Volz-Zang C, Waldhauser T, Schulte B, et al. Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. Eur J Clin Pharmacol. 1995;49(1-2):45-49.
  184. Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633-642.
  185. Kehe CR, Lasseter KC, Miller NC, et al. Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection. Ther Drug Monit. 1992;14(2):132-134.
  186. Kentala E, Kaila T, Iisalo E, et al. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. Int J Clin Pharmacol Ther Toxicol. 1990;28(9):399-404.
  187. Kamimori GH, Smallridge RC, Redmond DP, et al. The effect of exercise on atropine pharmacokinetics. Eur J Clin Pharmacol. 1990;39(4):395-397.
  188. Friedl KE, Hannan CJ Jr, Schadler PW, et al. Atropine absorption after intramuscular administration with 2-pralidoxime chloride by two automatic injector devices. J Pharm Sci. 1989;78(9):728-731.
  189. Kentala E, Kaila T, Kanto J. Intramuscular atropine in elderly people: pharmacokinetic studies using the radioreceptor assay and some pharmacodynamic responses. Pharmacol Toxicol. 1989;65(2):110-113.
  190. Harrington L. Clinical practice. Administer single-site 30mL intramuscular injection? MEDSURG Nursing. 2005;14(6):379-382.
  191. Wynaden D, Landsborough I, Chapman R, et al. Establishing best practice guidelines for administration of intra muscular injections in the adult: a systematic review of the literature. Contemporary Nurse. 2005;20(2):267-277.
  192. Greenway K. Using the ventrologluteal site for intramuscular injection. Nursing Standard. 2004;18(25):39-42.
  193. Nicoll LH, Hesby A. Intramuscular injection: an integrative research review and guideline for evidence-based practice. Applied Nursing Res. 2002;15(3):149-162.
  194. Rodger MA, King L. Drawing up and administering intramuscular injections: a review of the literature. J Adv Nursing. 2000;31(3):574-582.
  195. Hopkins U, Arias CY. Large-volume IM injections: a review of best practices. Oncology Nurse Advisor. 2013;32-37.
  196. Cyclokapron Product Monograph, 100mg/ml Tranexamic Acid Injection House Std., Antifibrinolytic agent, Pfizer Canada Inc, 17,300 Trans-Canada Highway, February 22, 2016, Control No. 185812.
  197. Marmo E, Di Nola R, Rossi F. Cardiovascular effects of antifibrinolytic drugs. Res Commun Chem Pathol Pharmacol. 1973;6:137-150.

Intramuscular Tranexamic Acid in Tactical and Combat Settings

Spring 2018

Erik N. Vu, MSM, MD; Wilson C. Y. Wan, MD; Titus Yeung, MD; Dave Callaway, MD

References

  1. Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6 suppl 5):S431-S437.
  2. Butler FK Jr, Blackbourne LH, Battlefield trauma care then and now: a decade of Tactical Combat Casualty Care. J Trauma Acute Care Surg. 2013;73(6 suppl 5):S395-402.
  3. Shakur H, Roberts I, Bautista R, et al. Effects of tran-examic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
  4. Morrison JJ, Dubose JJ, Rasmussen TE, et al. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147(2):113-119.
  5. Engels PT, et al. IV access in bleeding trauma patients: a performance review. Injury, 2014;45(1):77-82.
  6. Nadler R, et al. Intravenous access in the prehospital [combat] settings: what can be learned from point-of-injury experience. J Trauma Acute Care Surg, 2015;79(2):221-226.
  7. Rizoli SB, et al. Clotting factor deficiency in early trauma-associated coagulopathy. J Trauma, 2011;71(5 suppl 1):S427-S434.
  8. Brohi K, et al. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis, J Trauma-Injury Infection Crit Care. 2008;64(5):1211-1217.
  9. Holcomb JB, et al. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) Study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013;148(2):127-136.
  10. Holcomb JB, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma. The PROPPR Randomized Clinical Trial. JAMA. 2015;313(5):471-482.
  11. AP Cap, et al. Timing and location of blood product transfusion and outcomes in massively transfused combat casualties. J Trauma Acute Care Surg. 2012;73(2 suppl 1):S89-S94.
  12. Cotton BA, Reddy N, Hatch QM, et al. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Ann Surg. 2011;254(4):598-605.
  13. Mrochuk M, O’Dochartaigh D, Chang E. Rural trauma patients cannot wait: tranexamic acid administration by helicopter emergency medical services. Air Med J. 2015;34(1):37-39.
  14. Cole E, Davenport R, Willett K, et al. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg. 2015;261(2):390-394.
  15. Tengborn L, Blomback M, Berntorp E. Tranexamic acid: an old drug still going strong and making a revival. Thromb Res. 2014; Nov 20.
  16. Zehtabchi S, Abdel Baki SG, Falzon L, et al. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med. 2014;32(12):1503-1509.
  17. Nadler R, Gendler S, Benov A, et al. Tranexamic acid at the point of injury: the Israeli combined civilian and military experience. J Trauma Acute Care Surg. 2014;77(3 suppl 2):S146-S150.
  18. Ackery A, Rizoli S. Tranexamic acid for trauma-related hemorrhage. CMAJ. 2014;186(15):E587.
  19. Dakir A, Ramalingam B, Ebenezer V, et al. Efficacy of tranexamic acid in reducing blood loss during maxillofacial trauma surgery: a pilot study, J Clin Diagn Res. 2014;8(5):ZC06-ZC08.
  20. Valle EJ, Allen CJ, Van Haren RM, et al. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014;76(6):1373-1378.
  21. ailey AM, Baker SN, Weant KA. Tranexamic acid for trauma-related hemorrhage. Adv Emerg Nurs J. 2014;36(2):123c131.
  22. Schochl H, Schlimp CJ, Maegele M. Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? Shock. 2014;41(suppl 1):44-46.
  23. Lipsky AM, Abramovich A, Nadler R, et al. Tranexamic acid in the prehospital setting: Israel Defense Forces’ initial experience. Injury. 2014;45:66-70.
  24. Mitra B, Mazur S, Cameron PA, et al. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australas. 2014;26(2):194-197.
  25. Livingstone C. Tranexamic acid in patients with major injuries and blood loss. Emerg Nurse. 2013;21(8):24-26.
  26. Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, et al. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial, BMC Emerg Med. 2013;13:20.
  27. Vu EN, Schlamp RS, Wand RT, et al. Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation. Air Med J. 2013;32(5):289-292.
  28. Perel P, Prieto-Merino D, Shakur H, et al. Development and validation of a prognostic model to predict death in patients with traumatic bleeding, and evaluation of the effect of tranexamic acid on mortality according to baseline risk: a secondary analysis of a randomised controlled trial. Health Technol Assess. 2013;17(24):1-45, v-vi.
  29. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1-79.
  30. Rappold JF, Pusateri AE. Tranexamic acid in remote damage control resuscitation. Transfusion. 2013;53(suppl 1):96S-99S.
  31. Pusateri AE, Weiskopf RB, Bebarta V, et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39(2):121-126.
  32. Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality. Prescrire Int. 2013;22(140):189-190.
  33. Morrison JJ, Ross JD, Dubose JJ, et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg. 2013;148(3):218-225.
  34. Perel P, Ker K, Morales Uribe CH, et al. Tranexamic acid for reducing mortality in emergency and urgent surgery. Cochrane Database Syst Rev. 2013;1.
  35. Roberts I, Perel P, Prieto-Merino D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012;345:e5839.
  36. Levi M. Should antifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol. 2012;25(3):385-388.
  37. Weber BJ, Kjelland CB. The use of tranexamic acid for trauma patients? CJEM. 2012;14(1):53-56.
  38. Perel P, Al-Shahi Salman R, Kawahara T, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury-a nested randomised, placebo-controlled trial. Health Technol Assess. 2012;16(13):iii-xii, 1c54.
  39. Ker K, Kiriya J, Perel P, et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med. 2012;12:3.
  40. Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012;12:CD004896.
  41. Cap AP, Baer DG, Orman JA, et al. Tranexamic acid for trauma patients: a critical review of the literature. J Trauma. 2011;71(1 suppl):S914.
  42. CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ. 2011;343:d3795.
  43. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101, 101 e1-2.
  44. Hunt BJ. The current place of tranexamic acid in the man-agement of bleeding, Anaesthesia. 2015;70(suppl 1):50-53, e18.
  45. Zhang F, et al. Effectiveness of tranexamic acid in reducing blood loss in spinal surgery: a meta-analysis. BMC Musculoskelet Disord. 2014;15(1):448.
  46. Breau RH, et al. The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis. Transfus Med Rev. 2014;28(3):145-155.
  47. Whiting DR, et al. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res. 2014;472(1):66-72.
  48. Zehtabchi S, et al. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med. 2014;32(12):1503-1509.
  49. Zhang Y, et al. Safety and efficacy of intra-articular injection of tranexamic acid in total knee arthroplasty. Orthopedics. 2014;37(9):e775-e782.
  50. Moen CA, et al. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg. 2013;17(6):991-994.
  51. Fu DJ, et al. Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Traumatol. 2013;16(2):67v76.
  52. Gruen RL, et al. Trauma and tranexamic acid. Med J Aust. 2013;199(5):310-311.
  53. No authors listed. Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality. Prescrire Int. 2013; 22(140):189v190.
  54. No authors listed. Tranexamic acid and thrombosis. Prescrire Int. 2013;22(140):182-183.
  55. Gybel MK, et al. Cardiac arrest caused by massive pulmonary embolism during treatment with tranexamic acid. Ugeskr Laeger. 2013;175(20):1426-1427.
  56. Munoz Gomez M, Paramo Fernandez JA. Intravenous administration of tranexamic acid to decrease bleeding and transfusion in knee and hip prosthetic surgery: is it safe and cost-effective? Med Clin (Barc). 2013;141(5):207-209.
  57. Panteli MC, et al. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis, Knee. 2013; 20(5):300-309.
  58. Leminen H, Hurskainen R. Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. Int J Womens Health. 2012;4:413-421.
  59. Yang ZG, et al. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012;94(13):1153-1159.
  60. Onodera TT, et al. Risk of deep venous thrombosis in drain clamping with tranexamic acid and carbazochrome sodium sulfonate hydrate in total knee arthroplasty. J Arthroplasty. 2012;27(1):105-108.
  61. Ross J, Al-Shahi Salman R. The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. Curr Drug Saf. 2012;7(1):44-54.
  62. Krivokuca I, Lammers JW. Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. Clin Appl Thromb Hemost. 2011;17(1):106-107.
  63. Alshryda SP, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis, J Bone Joint Surg Br. 2011;93(12):1577-1585.
  64. Marquez-Martin ED, et al. Endobronchial administration of tranexamic acid for controlling pulmonary bleeding: a pilot study. J Bronchology Interv Pulmonol. 2010;17(2):122-125.
  65. Ide MD, et al. Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesthesiol. 2010;24(1):96-106.
  66. Sundstrom AH, et al. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the -General Practice Research Database. BJOG. 2009;116(1):91-97.
  67. Kagoma YK, et al. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thrombosis Res. 2009;123(5):687-696.
  68. Escher R. Extensive venous thrombosis following administration of high-dose glucocorticosteroids and tranexamic acid in relapsed Evans syndrome. Blood Coagul Fibrinolysis. 2008;19(7):741-742.
  69. Ghosh K. Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis, Thromb Haemost. 2008;100(1):162-164.
  70. Gluud LL, et al. Systematic review: tranexamic acid for upper gastrointestinal bleeding, Aliment Pharmacol Therap. 2008; 27(9):752-758.
  71. Fraser IS, et al. A benefit-risk review of systemic haemostatic agents-part 1: in major surgery. Drug Safety. 2008;31(3):217-230.
  72. Ip PP, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug–induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol. 2007 Aug;31(8):1215-24.
  73. De Wolf A, Abecassis M. Is antifibrinolytic drug use in liver transplantation associated with an increased risk of thromboembolic events? Commentary. Nat Clin Pract Gastroenterol Hepatol. 2007;4(8):422-423.
  74. Molenaar IQ, et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transpl. 2007;7(1):185-194.
  75. Groenland TH, Porte RJ. Antifibrinolytics in liver transplantation. Int Anesthesiol Clin. 2006;44(3):83-97.
  76. Hynes MC, et al. The use of tranexamic acid to reduce blood loss during total hip arthroplasty: an observational study. Ann R Coll Surg Engl. 2005;87(2):99-101.
  77. Idbaih AI, et al. Thrombotic cocktail in stroke. Neurology. 2005;64(2):334.
  78. Levin MD, et al. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica. 2003;88(6):Ecr21.
  79. Taparia M, et al. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol. 2002;68(5):307-309.
  80. Berntorp EC, et al. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86(2):714-715.
  81. Howes JP, et al. Tranexamic acid reduces blood loss after knee arthroplasty. J Bone Joint Surg Br. 1996;78(6):995-996.
  82. Lindoff C, et al. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993;70(2):238-240.
  83. Bekassy Z, Astedt B. Treatment with the fibrinolytic inhibitor tranexamic acid-risk for thrombosis? Acta Obstet Gynecol Scand. 1990;69(4):353-354.
  84. Snir MR, et al. Central venous stasis retinopathy following the use of tranexamic acid, Retina. 1990;10(3):181-184.
  85. Woo KS, et al. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989;43(12):465-466.
  86. Woo KS, et al. Massive pulmonary thromboembolism after antifibrinolytic therapy. Ann Emerg Med. 1989;18(1):116-117.
  87. Endo Y, et al. Idiopathic thrombocytopenic purpura, associated with deep vein thrombosis induced by tranexamic acid. Rinsho Ketsueki. 1988;29(2):186-188.
  88. Humbert P, et al. Tranexamic acid and thrombosis of the superior longitudinal sinus. Therapie. 1987;42(1):65-66.
  89. Agnelli G, et al. Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report. Br J Obstet Gynaecol. 1982;89(8):681-682.
  90. No authors listed. Thromboembolism and eye diseases caused by tranexamic acid. Lakartidningen. 1980;77(52):4974-4975.
  91. Gelmers HJ. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochir (Wien). 1980;52(1-2):45-50.
  92. Davies D, Howell DA. Tranexamic acid and arterial thrombosis. Lancet. 1977;1(8001):49.
  93. Rydin E, Lundberg PO. Tranexamic acid and intracranial thrombosis [letter]. Lancet. 1976;2(7975):49.
  94. Nadler R, et al. Tranexamic acid at the point of injury: the Israeli combined civilian and military experience. J Trauma Acute Care Surgery. 2014;77(3 suppl 2):S146-S150.
  95. Ackery A, Rizoli S. Tranexamic acid for trauma-related hemorrhage. CMAJ. 2014;186(15):E587.
  96. Valle EJ, Allen CJ, Van Haren RM, et al. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014;76(6):1373-1378.
  97. Bailey AM, Baker SN, Weant KA. Tranexamic acid for trauma-related hemorrhage. Adv Emerg Nursing J. 2014;36(2):123-131; quiz 32-33.
  98. Mitra B, Mazur S, Cameron PA, et al. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australasia. 2014;26(2):194-197.
  99. Theusinger OM, Stein P, Spahn DR. Applying ‘Patient Blood Management’ in the trauma center. Curr Opin Anaesthesiol. 2014;27(2):225-232.
  100. Schochl H, Schlimp CJ, Maegele M. Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? Shock. 2014;41(suppl 1):44-46.
  101. Harvey V, Perrone J, Kim P. Does the use of tranexamic acid improve trauma mortality? Ann Emerg Med. 2014;63(4):460-462.
  102. Eckert MJ, Wertin TM, Tyner SD, et al. Tranexamic acid administration to pediatric trauma patients in a combat setting: the Pediatric Trauma and Tranexamic Acid Study (PED-TRAX). J Trauma Acute Care Surg. 2014;77(6):852-858.
  103. Stensballe J, Ostrowski SR, Johansson PI. Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol. 2014;27(2):212-218.
  104. Lipsky AM, Abramovich A, Nadler R, et al. Tranexamic acid in the prehospital setting: Israel Defense Forces’ initial experience. Injury. 2014;45(1):66-70.
  105. Livingstone C. Tranexamic acid in patients with major injuries and blood loss. Emerg Nurse. 2013;21(8):24-26.
  106. Vu EN, Schlamp RS, Wand RT, et al. Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation. Air Medical J. 2013;32(5):289-292.
  107. Napolitano LM, Cohen MJ, Cotton BA, et al. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013;74(6):1575-1586.
  108. Georgiou C, Neofytou K, Demetriades D. Local and systemic hemostatics as an adjunct to control bleeding in trauma. Am Surgeon. 2013;79(2):180-187.
  109. Rappold JF, Pusateri AE. Tranexamic acid in remote damage control resuscitation. Transfusion. 2013;53(suppl 1): 96S-99S.
  110. Pusateri AE, Weiskopf RB, Bebarta V, et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39(2):121-126. PMID:23222525.
  111. Goodloe JM, Howerton DS, McAnallen D, et al. TXA: a difference-maker for trauma patients. J Emerg Med Serv. 2013;38(4):60-65.
  112. Goodloe JM, Howerton DS, McAnallen D, et al. How can tranexamic acid help in EMS? TXA offers new hope for an old challenge in traumatic hemorrhagic shock. EMS World. 2013;42(5):I5-I6.
  113. Germans MR, Post R, Coert BA, et al. Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials [Electronic Resource]. 2013;14:143. TRIAL REGISTRATION: Nederlands Trial Register (Dutch Trial Registry) number NTR3272.
  114. Gruen RL, Jacobs IG, Reade MC. Trauma and tranexamic acid. Med J Australia. 2013;199(5):310-311.
  115. Reade MC, Pitt V, Gruen RL. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;40(2):160-161.
  116. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17(2).
  117. Riha GA, Schreiber MA. Update and new developments in the management of the exsanguinating patient. J Intens Care Med. 2013;28(1):46-57.
  118. Schochl H, Schlimp CJ, Voelckel W. Potential value of pharmacological protocols in trauma. Curr Opin Anaesthesiol. 2013;26(2):221-229.
  119. Morrison JJ, Ross JD, Dubose JJ, et al. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg. 2013;148(3):218-225.
  120. Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012;12:CD004896.
  121. Gruen RL, Reade MC. Administer tranexamic acid early to injured patients at risk of substantial bleeding, BMJ. 2012; 345:e7133.
  122. Roberts I, Perel P, Prieto-Merino D, et al; Collaborators CRASH. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012;345:e5839.
  123. Boling B, Moore K. Tranexamic acid (TXA) use in trauma. J Emerg Nursing. 2012;38(5):496-497.
  124. Levi M. Should antifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol. 2012;25(3):385-388.
  125. Ker K, Kiriya J, Perel P, et al. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med. 2012;12:3.
  126. Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al; Collaborators CRASH. CRASH-3: tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial, Trials [Electronic Resource]. 2012;13:87. TRIAL REGISTRATION: Current Controlled Trials ISRCTN15088122; ClinicalTrials.gov NCT01402882.
  127. Grottke O. Coagulation management. Curr Opin Crit Care. 2012;18(6):641-646.
  128. Theusinger OM, Madjdpour C, Spahn DR. Resuscitation and transfusion management in trauma patients: emerging concepts. Curr Opin Crit Care. 2012;18(6):661-670.
  129. Perel P, Al-Shahi Salman R, Kawahara T, et al. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury-a nested randomised, placebo-controlled trial, Health Technology Assessment (Winchester, England). 2012;16(13):iii-xii, 1-54. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86750102.
  130. Culligan WB, Tien HC. Tranexamic acid autoinjector for prehospital care of noncompressible hemorrhage. J Trauma-Injury Infection Crit Care. 2011;71(5 suppl 1):S501-S502.
  131. Yeguiayan JM, Rosencher N, Vivien B. Early administration of tranexamic acid in trauma patients. Lancet. 2011; 378(9785):27-28; author reply 8.
  132. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101, 101.e1-e2.
  133. Curry N, Hopewell S, Doree C, et al. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care. 2011;15(2).
  134. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
  135. Griffee MJ, DeLoughery TG, Thorborg PA. Coagulation management in massive bleeding. Curr Opin Anaesthesiol. 2010;23(2):263-268.
  136. Mylankal KJ, Wyatt MG. Control of major haemorrhage. Surgery. 2010;28(11):556-562.
  137. Levine JM. Critical care management of subarachnoid hemorrhage. Curr Treat Options Neurol. 2009;11(2):126-136.
  138. Wise A, Clark V. Strategies to manage major obstetric haemorrhage. Curr Opin Anaesthesiol. 2008;21(3):281-287.
  139. Cocchi MN, Kimlin E, Walsh M, et al. Identification and resuscitation of the trauma patient in shock. Emerg Med Clin N Am. 2007;25(3):623-642.
  140. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11(R17).
  141. Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur Heart J Suppl. 2006;8(G):G38-G45.
  142. Bugge W, Hjelmeland K, Soreide E, et al. Transfusion vs. alternative treatment modalities in acute bleeding: a systematic review. Acta Anaesthesiol Scand. 2006;50(8):920-931.
  143. Bailey AM, Baker SN, Weant KA. Tranexamic acid for trauma-related hemorrhage. Adv Emerg Nurs J. 2014;36(2):123-131; quiz 32-33.
  144. Waldow T, Szlapka M, Haferkorn M, et al. Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc. 2013;55(4):457-468.
  145. Iwai T, Tsuji S, Tomita T, et al. Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. Int Orthop. 2013 Mar;37(3):441-415.
  146. Grassin-Delyle S, Couturier R, Abe E, et al. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology. 2013;118(4):853-862.
  147. Koster A, Borgermann J, Zittermann A, et al. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome, Br J Anaesth. 2013;110(1):34-40.
  148. Abbasi H, Behdad S, Ayatollahi V, et al. Comparison of two doses of tranexamic acid on bleeding and surgery site quality during sinus endoscopy surgery. Adv Clin Exp Med. 2012;21(6):773-780.
  149. Maniar RN, Kumar G, Singhi T, et al. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012;470(9):2605-2612.
  150. Bojko B, Vuckovic D, Mirnaghi F, et al. Therapeutic monitoring of tranexamic acid concentration: high-throughput analysis with solid-phase microextraction. Ther Drug Monit. 2012;34(1):31-37.
  151. Jimenez JJ, Iribarren JL, Brouard M, et al. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose–dependent, phase IV clinical trial. J Cardiothorac Surg. 2011;6:138.
  152. Keyl C, Uhl R, Beyersdorf F, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg. 2011;39(5):e114-e121.
  153. Sander M, Spies CD, Martiny V, et al. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care. 2010;14(4):R148.
  154. Murkin JM, Falter F, Granton J, et al. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010;110(2):350-353.
  155. Colomina MJ, Bago J, Fuentes I, Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: a prospective, randomized, double-blind, placebo-controlled study. Spine 2008;33:2577-2580, Spine (Phila Pa 1976). 2009;34(16):1740-1741.
  156. Nuttall GA, Gutierrez MC, Dewey JD, et al. A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22(2):230-235.
  157. Casati V. About dosage schemes and safety of tranexamic acid in cardiac surgery. Anesthesiology. 2003;99(1):236.
  158. Puigdellivol E, Carral ME, Moreno J, et al. Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol. 1985;23(6):298-301.
  159. Abbara C, Rousseau JM, Lelievre B, et al. Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Br J Pharmacol. 2010;161(8):1857-1867.
  160. Corvino TF, Nahata MC, Angelos MG, et al. Availability, stability, and sterility of pralidoxime for mass casualty use. Ann Emerg Med. 2006;47(3):272-277.
  161. Jovanovic D. Pharmacokinetics of pralidoxime chloride: a comparative study in healthy volunteers and in organophosphorus poisoning. Arch Toxicol. 1989;63(5):416-418.
  162. Edwards ES, Gunn R, Simons ER, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol. 2013;111(2):132-137.
  163. Sclar DA. Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery. Ther Clin Risk Manage. 2013;9(1):149-151.
  164. Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol. 2006;117(2):398-403.
  165. Graf CJ, Woodworth JR, Seger ME, et al. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci. 1999;88(10):991-995.
  166. Pontiroli AE, Calderara A, Perfetti MG, et al. Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. Eur J Clin Pharmacol. 1993;45(6):555-558.
  167. Muhlhauser I, Koch J, Berger M. Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care. 1985;8(1):39-42.
  168. Garnett WR, Barr WH, Edinboro LE, et al. Diazepam autoinjector intramuscular delivery system versus diazepam rectal gel: a pharmacokinetic comparison. Epilepsy Res. 2011;93(1):11-16.
  169. Lamson MJ, Sitki-Green D, Wannarka GL, et al. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single–centre study. Clin Drug Investig. 2011;31(8):585-597.
  170. Abbara C, Rousseau JM, Turcant A, et al. Bioavailability of diazepam after intramuscular injection of its water-soluble prodrug alone or with atropine-pralidoxime in healthy volunteers. Br J Pharmacol. 2009;157(8):1390-1397.
  171. Lehmann C, Wannarka GL. Bioavailability and dose proportionality of intramuscular diazepam administered by autoinjector. J Clin Pharmacol. 2008;48(4):436-444.
  172. Elisabeth R, Treluyer JM, Pons G. Pharmacokinetic optimisation of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet. 1999;36(6):409-424.
  173. Hung OR, Dyck JB, Varvel J, et al. Comparative absorption kinetics of intramuscular midazolam and diazepam. Can J Anaesth. 1996;43(5 Pt 1):450-455.
  174. Nilsson A. Pharmacokinetics of benzodiazepines and their antagonists. Bailliere’s Clin Anaesthesiol. 1991;5(3):615-634.
  175. Brazeau GA, Fung HL. Effect of organic cosolvent-induced skeletal muscle damage on the bioavailability of intramuscular [14C]diazepam, J Pharm Sci. 1990;79(9):773-777.
  176. Saletu B, Anderer P, Kinsperger K, et al. Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping. Int Clin Psychopharmacol. 1988;3(4):287-323.
  177. Bertler A, Lindgren S, Magnusson JO, et al. Intramuscular bioavailability of chlorazepate as compared to diazepam. Eur J Clin Pharmacol. 1985;28(2):229-230.
  178. Divoll M, Greenblatt DJ, Ochs HR, et al. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg. 1983;62(1):1-8.
  179. von Dardel O, Mebius C, Mossberg T, et al. Fat emulsion as a vehicle for diazepam. A study of 9492 patients. Br J Anaesth. 1983;55(1):41-47.
  180. Magnussen I, Oxlund HR, Alsbirk KE, et al. Absorption of diazepam in man following rectal and parenteral administration. Acta Pharmacol Toxicol (Copenh). 1979;45(2):87-90.
  181. Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm. 1977;34(9):965-968.
  182. Korttila K, Sothman A, Andersson P. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. Acta Pharmacol Toxicol (Copenh). 1976;39(1):104-117.
  183. Volz-Zang C, Waldhauser T, Schulte B, et al. Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. Eur J Clin Pharmacol. 1995;49(1-2):45-49.
  184. Ali-Melkkila T, Kanto J, Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993;37(7):633-642.
  185. Kehe CR, Lasseter KC, Miller NC, et al. Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection. Ther Drug Monit. 1992;14(2):132-134.
  186. Kentala E, Kaila T, Iisalo E, et al. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. Int J Clin Pharmacol Ther Toxicol. 1990;28(9):399-404.
  187. Kamimori GH, Smallridge RC, Redmond DP, et al. The effect of exercise on atropine pharmacokinetics. Eur J Clin Pharmacol. 1990;39(4):395-397.
  188. Friedl KE, Hannan CJ Jr, Schadler PW, et al. Atropine absorption after intramuscular administration with 2-pralidoxime chloride by two automatic injector devices. J Pharm Sci. 1989;78(9):728-731.
  189. Kentala E, Kaila T, Kanto J. Intramuscular atropine in elderly people: pharmacokinetic studies using the radioreceptor assay and some pharmacodynamic responses. Pharmacol Toxicol. 1989;65(2):110-113.
  190. Harrington L. Clinical practice. Administer single-site 30mL intramuscular injection? MEDSURG Nursing. 2005;14(6):379-382.
  191. Wynaden D, Landsborough I, Chapman R, et al. Establishing best practice guidelines for administration of intra muscular injections in the adult: a systematic review of the literature. Contemporary Nurse. 2005;20(2):267-277.
  192. Greenway K. Using the ventrologluteal site for intramuscular injection. Nursing Standard. 2004;18(25):39-42.
  193. Nicoll LH, Hesby A. Intramuscular injection: an integrative research review and guideline for evidence-based practice. Applied Nursing Res. 2002;15(3):149-162.
  194. Rodger MA, King L. Drawing up and administering intramuscular injections: a review of the literature. J Adv Nursing. 2000;31(3):574-582.
  195. Hopkins U, Arias CY. Large-volume IM injections: a review of best practices. Oncology Nurse Advisor. 2013;32-37.
  196. Cyclokapron Product Monograph, 100mg/ml Tranexamic Acid Injection House Std., Antifibrinolytic agent, Pfizer Canada Inc, 17,300 Trans-Canada Highway, February 22, 2016, Control No. 185812.
  197. Marmo E, Di Nola R, Rossi F. Cardiovascular effects of antifibrinolytic drugs. Res Commun Chem Pathol Pharmacol. 1973;6:137-150.